Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT04032418
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Palliative Management of Inoperable Malignant Bowel Obstruction
Phase 2
Terminated
- Conditions
- Malignant Bowel Obstruction
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT04027348
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Impact of Early Mobility on Post-Surgery Recovery in Patients Undergoing Oncologic Surgeries
Not Applicable
Terminated
- Conditions
- Malignant Neoplasm
- Interventions
- Other: Best PracticeOther: Physical ActivityOther: Questionnaire Administration
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT04000581
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Phase 1
Recruiting
- Conditions
- Metastatic Bone SarcomaMetastatic Unresectable SarcomaResectable SarcomaMetastatic Malignant Neoplasm in the LungMetastatic Soft Tissue SarcomaColorectal Cancer
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 99
- Registration Number
- NCT03965234
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
Phase 2
Withdrawn
- Conditions
- Metastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaUnresectable Renal Pelvis Urothelial CarcinomaUnresectable Ureter Urothelial Carcinoma
- Interventions
- Biological: PembrolizumabBiological: Autologous Tumor Infiltrating Lymphocytes LN-145Biological: Aldesleukin
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT03935347
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant
Phase 2
Completed
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation RecipientOsteoporosisOsteopenia
- Interventions
- Biological: Denosumab
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03925532
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈCleveland Clinic, Cleveland, Ohio, United States
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Phase 2
Recruiting
- Conditions
- Prostate AdenocarcinomaStage II Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage I Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8
- Interventions
- Drug: EC AspirinProcedure: Radical Prostatectomy
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03899987
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
Not Applicable
Recruiting
- Conditions
- Breast CarcinomaHealthy Subject
- Interventions
- Procedure: Photoacoustic Imaging
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 400
- Registration Number
- NCT03897270
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Experimental Tobacco Marketplace in Regulating Flavored Tobacco Products in Menthol Cigarette Smokers
Not Applicable
Terminated
- Conditions
- Cigarette Smoking
- Interventions
- Behavioral: Smoking Cessation InterventionOther: Functional AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 103
- Registration Number
- NCT03897530
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients
Not Applicable
Completed
- Conditions
- Hematologic and Lymphocytic DisorderMalignant NeoplasmParentGuardian
- Interventions
- Other: Educational ActivityProcedure: Patient MonitoringOther: Questionnaire Administration
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT03895918
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States